BUSINESS
New JCR President Confident in 100 Billion Yen Sales Target in 2030s
JCR Pharmaceuticals’ new president Hiroyuki Sonoda expressed his confidence that the company can achieve its goal of 100 billion yen in annual sales in the 2030s, driven by products such as Izcargo (pabinafusp alfa) and a recently licensed Duchenne therapy.…
To read the full story
Related Article
- JCR Expects Strong Returns from Recently In-Licensed DMD Drug: CEO
January 26, 2026
BUSINESS
- Shionogi Nets 4th Straight Year of Record Earnings on Torii Deal, HIV Royalties
May 13, 2026
- Santen’s Eylea Sales Fall 15.9% amid Re-Pricing, Biosimilar Entry
May 13, 2026
- Fuji’s Eylea Biosimilar Logs 776 Million Yen in First 3 Months
May 13, 2026
- Japan Ethical Drug Sales Climb 9.3% in March: Crecon
May 13, 2026
- Daiichi Targets 3 Trillion Yen Sales by FY2030, Global Top-5 Oncology Spot
May 12, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





